What vitamin K1 is

Vitamin K is a family of fat-soluble naphthoquinones. Within K1 there are two common terms: phylloquinone refers to the form found naturally in green leafy vegetables, while phytonadione (phytomenadione) usually denotes the synthetic form — cosmetics use the single INCI name PHYTONADIONE. This article concerns cosmetic use, which is an entirely different matter from injectable pharmaceutical vitamin K1.

Its classic role in the body is as a cofactor for gamma-glutamyl carboxylase, participating in the carboxylation and activation of proteins including clotting factors — textbook biochemistry. But the line must be drawn immediately: this is a nutritional and pharmacological fact that cannot be carried into cosmetic claims. Cosmetics may not claim to affect blood clotting, improve vascular conditions or deliver any therapeutic effect.

Physico-chemically it is a yellow to orange-yellow viscous oil: fat-soluble, water-insoluble, and highly sensitive to light (especially UV) and oxidation. Those three facts dictate its place in a formula: oil phase, light protection, antioxidant partner.

Ingredient fact box

How it works, plainly

Start with the causes of under-eye darkness, or you cannot judge whether this ingredient fits. There are four common types: vascular (thin periorbital skin lets vessels or pooled blood show through as a bluish-purple cast), pigmentary (melanin deposition, brownish), structural (shadowing from tear troughs and eye bags) and mixed (a combination — the majority of cases).

• Where the hypothesis starts: part of vascular darkness relates to local deposition of haemoglobin breakdown products (such as haemosiderin) after red cells leak out. The established biochemistry of vitamin K in the relevant metabolic pathways led researchers to propose that topical application might help improve that appearance.
• How it is stated in cosmetics: under that hypothesis, vitamin K1 is positioned in eye creams as "helps reduce the look of bluish under-eye discolouration and darkness" — acting on appearance, with the pathway understood as supporting local metabolic and recovery processes.
• The evidence reality to accept: publicly available human studies are few, generally small, and inconsistent in their conclusions. Many used vitamin K in combination with other actives such as retinol or caffeine, so any effect cannot be attributed to K1 alone.

An honest caveat: the human evidence for vitamin K1 on under-eye darkness is weaker than for caffeine or niacinamide, and existing studies do not support "removes dark circles" level claims. Treat it as one component of a combined system, not a standalone hero active. Search PubMed for "vitamin K", "phytonadione", "periorbital" and "dark circles" to review the primary literature yourself. Claims should read "helps reduce the look of under-eye darkness".

Best-fitting formats

Use level and formulation notes (verify by bench trial)

Common reference level: as pure phytonadione, commercial eye formulas commonly sit around 0.1%–1%, mostly 0.1%–0.5%. For pre-dispersed or encapsulated grades, convert by the active content on the COA. More important: confirm the target market's conditions of use and any limit before discussing load level.

• Light stability is issue #1. K1 is light-sensitive, especially to UV; a clear bottle under retail spotlights can strip meaningful activity within weeks. Fix it with opaque or amber packaging, light-blocking internal coatings, nitrogen-flushed filling, and antioxidants such as vitamin E or BHT in the formula.
• Order of addition. Dissolve in the oil phase and add during cool-down below 60 °C with thorough dispersion; avoid prolonged high temperature and high-shear aeration.
• Colour management. K1 is a yellow to orange-yellow oil; higher levels tint white creams. Reduce the level, mask with base pigments, or embrace a "pale yellow cream" visual position.
• Water-based systems need solubilising. Serums, gels and mask essences must solubilise or emulsify it first, then prove no oil separation or layering over time.
• pH: hold 5.0–7.0; strongly alkaline conditions accelerate degradation of the naphthoquinone structure.
• Incompatibilities. Avoid strong oxidisers and high levels of metal ions; when combined with retinol, run stability and tolerance work separately for each.
• Stability protocol. 40 °C for 3 months, light exposure (visible and UV) and freeze–thaw cycling, with the key step being actual K1 assay rather than visual inspection alone.

The figures above are common reference levels for eye care formulas; the actual use level is set by the formulation engineer based on dosage form, compatibility and target-market rules. Permitted use conditions, limits and labelling requirements differ by market — complete a compliance review for each destination before shipment. All descriptions here are general cosmetic applications and appearance or skin-feel statements, not medical advice or efficacy guarantees.

Compliance and market notes (verify per target market)

• First action before the project starts: in some markets vitamin K1 (PHYTONADIONE) is an ingredient whose cosmetic usability must be confirmed first — always check its listing status and historical maximum use level in China's Inventory of Existing Cosmetic Ingredients in China (2021 edition), and its entry and conditions of use in EU COSING. Tooling up and sampling before this is confirmed is the single largest source of wasted budget in such a project.
• China: once listing is confirmed, claims must comply with the Cosmetic Supervision and Administration Regulation, cosmetic labelling rules and efficacy-claim evaluation rules; "brightening" or "reduces dullness" claims require substantiation on file.
• EU (EC) No 1223/2009: after confirming COSING status, complete the CPNP notification, PIF and CPSR. Claims must meet the Common Criteria for Cosmetic Claims, (EU) No 655/2013 — no implied pharmacological action.
• US MoCRA (2022): facility registration, product listing, safety substantiation, adverse-event reporting and record-keeping apply, with labelling under the FD&C Act and relevant 21 CFR provisions. Cosmetics do not undergo pre-market approval — never write "FDA approved".
• Claim red lines (critical): any medical wording touching blood clotting, blood vessels or circulation is prohibited — "boosts circulation", "improves clotting", "clears bruising". So are "treats dark circles" and "eliminates hyperpigmentation". Acceptable wording: "helps reduce the look of under-eye darkness", "helps soften the look of bluish discolouration".
• Japan / Korea / Middle East: the classification boundary for vitamin-type ingredients varies widely — verify per target market.

Ingredient pairings

• K1 + caffeine (1%–3%): the most sensible pair for under-eye darkness. Both address appearance pathways linked to the vascular type, and caffeine's immediate feel compensates for K1's slower timeline.
• K1 + niacinamide (2%–5%): hand pigmentary darkness to niacinamide, giving dual-pathway coverage — a far more realistic answer for mixed-type darkness.
• K1 + vitamin E (0.1%–1%) / BHT: not an efficacy pairing but a stability one — antioxidants slow the oxidative degradation of K1 itself and are effectively mandatory.
• K1 + ceramides + squalane: barrier support and a smooth skin feel, suited to gentle long-wear night eye creams.
• Use with care: with retinol, run stability and tolerance work separately for each; avoid strong oxidisers and high metal-ion loads; clear packaging and brightly lit shelving are the hidden killers of a K1 formula.

Formulation pairing cards

FAQ

Image briefs